US Prescription Drug Spending to Top $560bn in 2026

US prescription drug spending is forecast to exceed $560bn in 2026 as demand for GLP-1 obesity and diabetes treatments continues to rise.

iDexis Semaglutide Ban Ordered By High Court

iDexis semaglutide ban stops the pharmacy group from selling compounded weight-loss medicines while SAHPRA and the SAPC investigate.

Semaglutide Compounding Dispute: Novo Nordisk Heads To Court

The Semaglutide Compounding Dispute intensifies as Novo Nordisk takes iDexis to court over illegal manufacturing of weight-loss injections.